



**GIG**  
CYMRU  
**NHS**  
WALES

Bwrdd Iechyd Prifysgol  
Bae Abertawe  
Swansea Bay University  
Health Board



<b>Meeting Date</b>	<b>24 September 2020</b>		<b>Agenda Item</b>	<b>6.1(i)</b>
<b>Report Title</b>	<b>Research &amp; Development Annual Report</b>			
<b>Report Author</b>	Jemma Hughes, R&D Manager			
<b>Report Sponsor</b>	Dr Richard Evans, Medical Director			
<b>Presented by</b>	Dr Richard Evans, Medical Director			
<b>Freedom of Information</b>	Open			
<b>Purpose of the Report</b>	The purpose of this report is to provide the Board with an update on R&D activity within the Health Board, with a particular focus on the impact of the Covid-19 pandemic.			
<b>Key Issues</b>	<p>Swansea Bay UHB has positively contributed to urgent Public Health (UPH) priority Covid-19 studies.</p> <p>The vast majority of research programmes were halted at the outset of the pandemic and this has had a significant impact on finances and our ability to achieve targets.</p> <p>The process is underway to re-start paused studies and open new studies in a safe manner.</p>			
<b>Specific Action Required</b> <i>(please choose one only)</i>	<b>Information</b>	<b>Discussion</b>	<b>Assurance</b>	<b>Approval</b>
	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>
<b>Recommendations</b>	<p>Members are asked to:</p> <ul style="list-style-type: none"> <li>• <b>NOTE</b> the contents of the report; and</li> <li>• <b>ENDORSE</b> the re-opening of research activity across the HB, subject to appropriate Covid-19 safeguard measures being in place and the full agreement of any supporting services.</li> </ul>			

# RESEARCH AND DEVELOPMENT ANNUAL REPORT

## 1. INTRODUCTION

This report seeks to inform the Board on the current state of R&D activity within the Health Board, with a focus on the impact of the Covid-19 pandemic.

Appended to this report are two comprehensive performance data reports for 2019/20 provided by Health and Care Research Wales, which offer an overview of activity by each HB across Wales and compares Wales' performance to England. SBUHB compares favourably, reflecting the excellent commitment to R&D that HB staff continue to demonstrate (Appendix 1, Appendix 2)

## 2. BACKGROUND

Similar to other services, the arrival of the Covid-19 pandemic saw an abrupt halt to R&D activity across the Health Board. At the outset of the outbreak, the Health Board suspended 217 studies, as at 24<sup>th</sup> August 2020, 167 of those studies remain suspended as the teams begin the slow re-start process ensuring necessary adaptations are being made to conduct the studies in line with Covid-19 secure measures.

Staff conducting and supporting research activity have shown utmost resolve in responding to the crisis. First, whilst the majority of studies were paused, the clinical research teams ensured that patients enrolled in clinical studies remained safe, working closely with sponsors to ensure essential study visits and supply of investigational drug were continued, where this was deemed appropriate. Second, the response to national urgent Covid-19 research programmes by clinical and research staff has been highly commendable. R&D teams have worked at pace with consultant colleagues to assess feasibility and open national platform studies which sought to identify potential treatment solutions.

As noted in the Chief Medical Officers (CMO) letter dated 18<sup>th</sup> August 2020:

***'An example of the importance of research for patient care is the finding from the RECOVERY trial that dexamethasone reduces deaths by one-third in patients receiving invasive mechanical ventilation and by one-fifth in patients receiving oxygen. This finding has informed clinical practice worldwide and was down to your efforts in facilitating research in the NHS'.***

The CMO letter goes on to state that the success of the RECOVERY trial has resulted in its adoption as the main platform study across the UK for both publically funded phase II and phase III therapeutics. SBUHB has actively supported the Recovery trial, recruiting 50 patients. Other examples of Covid-19 studies supported by SBUHB staff include Genomicc and Remap Cap both ITU studies, where we have had the highest recruitment across Wales. A total of 20 Covid-19 studies have been opened or are in set up across the Health Board ranging from surveillance studies to more complicated phase 2 treatment studies (Appendix 3).

The rapid response process continues as new Covid-19 studies continue to be assessed in preparation for a potential second wave and, crucially capacity and capability to deliver vaccine studies is considered and secured. Simultaneously, the teams are beginning to re-start crucial studies which are contributing to the new evidence base for so many treatments in other disease areas and answer questions on important healthcare issues.

### **3. GOVERNANCE AND RISK ISSUES**

Halting research has had an inevitable impact on both financial risk to the HB (loss of commercial income) and in the inability to meet research performance targets set by both Welsh Government and study Sponsors. The potential reputational risk is mitigated however, in that both WG and study Sponsors do not intend to hold the HB to targets set prior to a worldwide pandemic. The key issue will be re-starting studies as soon as is feasible and safe. Recommencement of research activity is being overseen by the Restore and Recovery programme and Quality Impact Assessments submitted to ensure that clinical research is able to be conducted safely.

### **4. FINANCIAL IMPLICATIONS**

We have estimated a loss of ~£200K due to the halt of commercially funded clinical trials. Research staff funded out of commercial income, notably within our Joint Clinical Research Facility, present a real cost pressure to the HB as we operate a shared liability with Swansea University to cover their costs. Equally, some HB sponsored studies have required grant extensions and, if these are unfunded extensions, any staff employed under those grants are a potential financial risk to the HB. The R&D team are, therefore, seeking to secure costed grant extensions. The need to re-start studies as quickly as possible is critical if these risks are to be mitigated.

### **5. RECOMMENDATION**

Members are asked to:

- **NOTE** the contents of the report; and
- **ENDORSE** the re-opening of research activity across the HB, subject to appropriate Covid-19 safeguard measures being in place and the full agreement of any supporting services.

<b>Governance and Assurance</b>		
<b>Link to Enabling Objectives</b> (please choose)	<b>Supporting better health and wellbeing by actively promoting and empowering people to live well in resilient communities</b>	
	Partnerships for Improving Health and Wellbeing	<input checked="" type="checkbox"/>
	Co-Production and Health Literacy	<input checked="" type="checkbox"/>
	Digitally Enabled Health and Wellbeing	<input checked="" type="checkbox"/>
	<b>Deliver better care through excellent health and care services achieving the outcomes that matter most to people</b>	
	Best Value Outcomes and High Quality Care	<input checked="" type="checkbox"/>
	Partnerships for Care	<input checked="" type="checkbox"/>
	Excellent Staff	<input checked="" type="checkbox"/>
	Digitally Enabled Care	<input checked="" type="checkbox"/>
	Outstanding Research, Innovation, Education and Learning	<input checked="" type="checkbox"/>
<b>Health and Care Standards</b>		
(please choose)	Staying Healthy	<input type="checkbox"/>
	Safe Care	<input checked="" type="checkbox"/>
	Effective Care	<input checked="" type="checkbox"/>
	Dignified Care	<input type="checkbox"/>
	Timely Care	<input type="checkbox"/>
	Individual Care	<input type="checkbox"/>
	Staff and Resources	<input type="checkbox"/>
<b>Quality, Safety and Patient Experience</b>		
Improved patient experience through access to new treatments offered under research programmes.		
<b>Financial Implications</b>		
Improved financial position through re-start of commercially funded studies and re-start of grant-funded studies.		
<b>Legal Implications (including equality and diversity assessment)</b>		
Enabling compliance with UK Policy on Research Governance.		
<b>Staffing Implications</b>		
N/A		
<b>Long Term Implications (including the impact of the Well-being of Future Generations (Wales) Act 2015)</b>		
N/A		
<b>Report History</b>	N/A	
<b>Appendices</b>	<b>Appendix 1:</b> Health and Care Research Wales Finance Business Intelligence Pack 19/20 <b>Appendix 2:</b> Health and Care Research Wales NHS Wales Performance Report 19/20 <b>Appendix 3:</b> COVID-19 Research in Swansea Bay UHB	

# NHS Support & Delivery Research Funding & Financial Analysis 2019/20

Funding & Finance Business  
Intelligence Report

Version 1.0

31<sup>st</sup> July 2020

## How to use this business intelligence report (1)

This slide is part of the explanatory notes for the Support & Delivery Research Funding & Financial Analysis in NHS Wales – Funding & Finance business intelligence report 2019/20

These notes are to be used in conjunction with the following slides

### Business Intelligence report – slide layout

**Title:** concisely describes the data or information being conveyed.

**Explanation:** describes the data or information being conveyed in more detail than the title.

This may include items of note or caveats to explain the reasons for inclusion or exclusion of certain data or information.

**Data source:** describes the data or information source used to obtain data for interrogation or manipulation.



Title

Explanation including any items of note

Data source

Visual representation of the data or information

**Visual representation:** a visual (graphical or tabular) representation of the data following interrogation or manipulation.

Note: Any additional information included with the visual representation is intended to further explain the visual.

## Terminology, definitions and assumptions

This slide is part of the explanatory notes for the Support & Delivery Research Funding & Financial Analysis in NHS Wales – Funding & Finance business intelligence report 2019/20

These notes are to be used in conjunction with the following slides

### NHS Organisations

The NHS organisation names used in this report are those up to 31 Mar 2020. Where the organisation names are abbreviated, they are usually abbreviated as follows:

	NHS Organisation
AB	Aneurin Bevan University Health Board
BC	Betsi Cadwaladr University Health Board
CV	Cardiff and Vale University Health Board
CTM	Cwm Taf Morgannwg University Health Board
HD	Hywel Dda University Health Board
PT	Powys Teaching Health Board
PHW	Public Health Wales
SB	Swansea Bay University Health Board
VNHST	Velindre University NHS Trust
WAST	Welsh Ambulance Services NHS Trust

*NB: On 1<sup>st</sup> April 2019, responsibilities for healthcare services in Bridgend County Borough Council transferred to Cwm Taf University Health Board. To reflect the new boundary changes the health board names were also changed to Cwm Taf Morgannwg UHB and Swansea Bay UHB. This is reflected in the 2019/20 data. Note that any data for the NHS organisation for 2018/19 will be based on the boundaries pre-2019.*

### Support & Delivery Centre

The Support & Delivery centre provides national functions commissioned by Welsh Government and national research study support in partnership with NHS organisations

### Local Support & Delivery Funding

This is the allocation provided to NHS organisations to support their research management and delivery activities each year. The model up to 2019/20 was based on activity in previous years being used as a proxy to indicate future need.

### Health and Care Research Wales grant funding

This is funding provided for specific grant schemes for researchers, for example Research for Patient and Public Benefit (RfPPB)

### Research Directory

The following Health and Care Research Wales Directory categories are used in the report.

Classification		Definition
Portfolio	Non commercial	High-quality, non-commercial research studies that meet defined eligibility criteria for: - Source of funding; - Open competition; and - High quality peer review.
	Commercial	Commercial contract research studies that are industry funded and industry sponsored.
Non-Portfolio		Research studies that do not meet the portfolio eligibility criteria. This includes 'Pathway to Portfolio'.
	Pathway to Portfolio	Research studies with Health and Care Research Wales funded activities undertaken to inform the development of a portfolio study or a grant application for a portfolio study.

## Terminology, definitions and assumptions

This slide is part of the explanatory notes for the Support & Delivery Research Funding & Financial Analysis in NHS Wales – Funding & Finance business intelligence report 2019/20

These notes are to be used in conjunction with the following slides

### Definition of management, admin and delivery costs

For the purposes of the financial analysis, the following definitions have been used:

‘Management’ classed as any post or function/ service that manages and facilitates the research process.

‘Administration’ classed as posts carrying out admin tasks, without any mention of delivery (as reported within annual returns) (includes admin posts in the Support & Delivery Centre)

‘Delivery’ classed as any post that has patient contact or is undertaking study related procedures (including supporting services)

### Analysis for radiology studies

Analysis on studies that involve ionising radiation has included any study that has ticked the appropriate box in IRAS. However, this means that studies could involve ionising radiation only as part of standard care. There is currently no way to differentiate between specific research related ionising radiation and standard care without reviewing individual study protocols, which has not been possible for this analysis.

### Research Study Categories

The following complexity band have been used when categorising research studies. These bands differentiate between study complexity and their associated costs.

Complexity band	Definition
Interventional studies	A study where the participants’ exposure to a particular intervention (e.g. care pathway or lifestyle) is influenced by participating in the study (e.g. whether or not a participant receives a particular treatment will be determined by the research protocol).
Observational studies	A study in which the participants’ lifestyle or care pathway is not affected by being part of the study (e.g. the investigator does not determine whether or not participants receive or do not receive a particular treatment).
Large sample studies	A study where the total UK planned sample size (throughout the lifetime of the study), is equal to, or greater than 10,000 participants. This can be an observational or interventional study, but the key factor to determine the band is the total planned sample (participant) size of the study.
Commercial studies	Commercial contract research studies that are industry funded and industry sponsored.



# Contents

## **Investment of research related funding provided by Welsh Government\***

*\*not including commercial income generated by the NHS organisations*

1. Funding allocations for Support & Delivery
2. Local Support & Delivery Financial Analysis
3. Support & Delivery Centre funding

# Section 1

## Funding allocations for Support & Delivery

- Local Support & Delivery allocations
- Clinical Research Time Awards
- NHS Support Costs
- Excess Treatment Costs
- Learning & Development funds

### Note:

- The activity data presented in this section includes data from the NHS organisation's financial annual returns for 2018/19 and 2019/20.

## Summary of Support & Delivery funding

Distribution of Local Support and Delivery Funding, as derived through the Activity Based Funding Model for Wales, top sliced to fund the implementation of LPMS in 2018/19 and 2019/20.

Additional Support & Delivery funding was also provided in 2019/20, which is included in the figures.

Pathway to portfolio funding was provided through a national call in 2018/19 and has also been included in the total allocation for that year.

Source:

Support and Delivery Centre Allocations data and financial annual return


NHS Organisation	2017/18	2018/19	2019/20
Aneurin Bevan UHB	£1,108,753	£1,356,785	£1,508,579
Betsi Cadwaladr UHB	£2,156,736	£1,943,353	£1,611,219
Cardiff & Vale UHB	£5,640,721	£5,771,096	£5,560,535
Cwm Taf Morgannwg UHB	£1,029,340	£1,043,520	£1,473,592
Hywel Dda UHB	£934,825	£1,129,480	£995,699
Powys THB	£123,553	£112,949	£140,637
Public Health Wales	£209,713	£248,500	£209,713
Swansea Bay UHB	£2,741,747	£2,704,752	£2,404,307
Velindre NHS Trust	£896,201	£823,578	£779,489
Welsh Ambulance Service NHS Trust	£122,275	£167,280	£132,275
Centralised NHS Support Costs	£950,472	£1,180,904	£1,129,932
Local Portfolio Management System (LPMS)	£0	£92,400	£92,400
<b>Total</b>	<b>£15,914,336</b>	<b>£16,574,597</b>	<b>£16,038,377</b>
<b>Support &amp; Delivery Centre</b>	<b>£3,700,000</b>	<b>£3,700,000</b>	<b>£3,700,000</b>

Funding Award	2017/18	2018/19	2019/20
CRTA	£335,464	£429,794	£392,612
RfPPB	£907,135	£1,139,756	£914,001
Specialty Leads	£306,740	£266,182	£305,909
<b>Total</b>	<b>£1,549,339</b>	<b>£1,835,732</b>	<b>£1,612,522</b>

## Clinical Research Time Award (CRTA) Funding 2015/16 – 2019/20

This chart summarises the amount of CRTA funding provided to NHS Organisations in Wales from 2015/16 to 2019/20.

Clinical Research Time Award funding per year



Source:

Welsh Government

# Excess Treatment Cost and Support Cost spend

This chart summarises the overall Excess Treatment Cost and Support Cost provided by the Support and Delivery Centre in 2018/19 & 2019/20.


Note:

Please note that this chart currently includes additional organisations to NHS Organisations, the key for these are as follows:

**Key**

BU = Bristol University

CU – Cardiff University



Source:


Support & Delivery Centre ETC/SC financial records

## Learning & Development Awards 2017-2020

Summary of the amount of funding awarded to Support & Delivery staff from 2017-2020.

Source:.

S&DC Centre Learning & Development  
fund records



# Section 2

## Local Support & Delivery Financial Analysis

- Split of management, delivery and administration costs
- Delivery funding spend on:
  - Pharmacy
  - Radiology
  - Pathology
- Comparison of the per participant recruited figure per organisation
- Total development spend
- Cost recovery spend
- Analysis of research delivery WTE by staff bands

### Note:

- The activity data presented in this section includes data from the NHS organisation's financial annual returns for 2018/19 and 2019/20.

## Delivery, Management and Admin Costs

This chart shows the actual spend per NHS organisation on Delivery, Management, Admin costs for 2018/19 – 2019/20.

### Note:


**Delivery:** Patient Contact or undertake study procedures (including supporting services)

**Management:** Manage/facilitate the research process

**Admin:** Admin tasks and no mention of delivery (as reported in Annual Returns)

### Source:

2018/19, 2019/20 Annual Returns





# Proportion of Delivery, Management and Admin Staffing Costs

This chart shows the proportion of Management, Delivery and Admin spend by each NHS organisation from 2018/19 to 2019/20.

## Note:


**Delivery:** Patient Contact or undertake study procedures (including supporting services)

**Management:** Manage/facilitate the research process

**Admin:** Admin tasks and no mention of delivery (as reported in Annual Returns)

## Source:

2018/19, 2019/20 Annual Returns



## Delivery, Management and Admin Staffing Costs 2019/20

This table shows the amount of spend per NHS organisation on Delivery, Management, Admin costs in 2019/20 in detail.

Note:

**Delivery:** Patient Contact or undertake study procedures (including supporting services)

**Management:** Manage/facilitate the research process

**Admin:** Admin tasks and no mention of delivery (as reported in Annual Returns)

NB: Directors & Deputy Directors are net costs (Expenditure minus amount cost recovered from elsewhere)

Source:

2019/20 Annual Returns

	Management		Admin		Combined Management/Admin		Delivery		Directors & Deputy Directors	
	Posts that manage and facilitate the research process		Posts carrying out admin tasks, without any mention of delivery (as reported within annual returns)				Posts with patient contact or undertake study related procedures (including supporting services)			
	£	WTE	£	WTE	£	WTE	£	WTE	£	WTE
AB UHB	£251,536	5.48	£55,384	2.80	£306,920	8.28	£931,091	37.45	£182,321	1.80
	20%	12%	4%	6%	25%	18%	75%	82%	14.73%	3.94%
BC UHB	£160,743	4.80	£47,330	2.40	£208,073	7.20	£1,293,514	47.25	£55,242	0.60
	11%	9%	3%	4%	14%	13%	86%	87%	3.68%	1.10%
C&V UHB	£1,078,454	21.40	£159,235	9.85	£1,237,689	31.25	£4,609,512	142.47	£102,955	0.70
	18%	12%	3%	6%	21%	18%	79%	82%	1.76%	0.40%
CTM UHB	£199,497	5.25	£38,756	2.00	£238,253	7.25	£919,159	38.18	£24,686	0.20
	17%	12%	3%	4%	21%	16%	79%	84%	2.13%	0.44%
HD UHB	£151,455	3.50	£74,630	3.10	£226,084	6.60	£595,336	17.40	£21,368	0.30
	18%	15%	9%	13%	28%	28%	72%	73%	2.60%	1.25%
Powys THB	£57,165	1.50	£0	0.00	£57,165	1.50	£41,741	0.80	£0	0.00
	58%	65%	0%	0%	58%	65%	42%	35%	0.00%	0.00%
PHW	£82,496	1.80	£22,301	1.00	£104,797	2.80	£0	0.00	£35,165	0.30
	79%	64%	21%	36%	100%	100%	0%	0%	33.56%	10.71%
SB UHB	£554,171	13.81	£13,238	4.60	£567,409	18.41	£1,440,142	55.62	£25,000	0.20
	28%	19%	1%	6%	28%	25%	72%	75%	1.25%	0.27%
Velindre	£250,355	8.18	£13,084	1.00	£263,438	9.18	£398,377	48.06	£33,383	0.20
	38%	14%	2%	2%	40%	16%	60%	84%	5.04%	0.35%
WAST	£85,597	1.90	£0	0.00	£85,597	1.90	£27,509	0.71	£49,817	0.70
	76%	73%	0%	0%	76%	73%	24%	27%	44.04%	26.82%
All-Wales	£2,871,469	68	£423,957	27	£3,295,426	94	£10,256,380	388	£529,937	5
	21%	14%	3%	6%	24%	20%	76%	80%	3.91%	1.04%

# Percentage Split of Delivery and Development Expenditure

The chart shows the proportion of Delivery against Development spend by each NHS organisation from 2018/19 to 2019/20.


Note:

**Delivery:** Patient Contact or undertaking study procedures (including supporting services)

**Development** undertaking or supporting grant development.

Source:

2018/19, 2019/20 Annual Returns



## R&D Directors / R&D Leads Costs


The chart shows the comparison of R&D Director / Lead spend by each NHS organisation from 2018/19 to 2019/20.

### Note:

Includes any R&D Director / Lead and Deputy/Assistant Director costs reported in the Local Support and Delivery Annual Returns

### Source:

2018/19, 2019/20 Annual Returns




# All Wales Pharmacy, Radiology & Pathology expenditure

The chart summarises the All Wales spend on Pharmacy, Radiology and Pathology services from 2018/19 to 2019/20.

Note:  
Costs are those reported against Pharmacy, Radiology or Pathology Support Departments in Local Support and Delivery Annual Returns

Source:  
2018/19, 2019/20 Annual Returns



# Pharmacy costs per CTIMP study

The chart shows the amount of spend per CTIMP study at NHS organisations from 2018/19 to 2019/20.

## Note:


Costs are those reported against Pharmacy as the Support Department in Local Support and Delivery Annual Returns.

Studies have been identified as being a CTIMP (Clinical Trial of Investigational Medicinal Product) as indicated in the study IRAS form.


## Source:

2018/19, 2019/20 Annual Returns

Summary of Pharmacy Expenditure per CTIMP - 2019/20



Summary of Pharmacy Expenditure per CTIMP - 2018/19



# Pharmacy costs per participant recruited to CTIMP studies

The chart shows the amount of spend per participant recruited to CTIMP study at NHS organisations from 2018/19 to 2019/20.

## Note:


Costs are those reported against Pharmacy as the Support Department in Local Support and Delivery Annual Returns.

Studies have been identified as being a CTIMP (Clinical Trial of Investigational Medicinal Product) as indicated in the study IRAS form.


## Source:

2018/19, 2019/20 Annual Returns

Summary of Pharmacy Expenditure per CTIMP - 2019/20



Summary of Pharmacy Expenditure per CTIMP - 2018/19



# Radiology costs per study

The chart shows the amount of spend per Radiology study at NHS organisations from 2018/19 to 2019/20.

## Note:

Costs are those reported against Radiology as the Support Department in Local Support and Delivery Annual Returns.


Studies have been identified as using Radiology where indicated as using Ionising Radiation in the study IRAS form. *This means that they could involve ionising radiation as part of standard care.*

NB: Data has been updated in line with amended HARP data for 2018/19.


## Source:

2018/19, 2019/20 Annual Returns

### Summary of Radiology Expenditure per Study - 2019/20



### Summary of Radiology Expenditure per Study - 2018/19





## Radiology costs per participant

The chart shows the amount of spend per participant recruited to Radiology study at NHS organisations from 2018/19 to 2019/20.

### Note:

Costs are those reported against Radiology as the Support Department in Local Support and Delivery Annual Returns.


Studies have been identified as using Radiology where indicated as using Ionising Radiation in the study IRAS form. *This means that they could involve ionising radiation as part of standard care.*

NB: Data has been updated in line with amended HARP data for 2018/19.


### Source:

2018/19, 2019/20 Annual Returns

### Summary of Radiology Expenditure per Participant - 2019/20



### Summary of Radiology Expenditure per Participant - 2018/19



## Pathology Costs

The chart summarises the spend by NHS organisations on Pathology services from 2018/19 to 2019/20.


### Note:

Costs are those reported against Pathology as the Support Department in Local Support and Delivery Annual Returns.


### Source:

2018/19, 2019/20 Annual Returns

### Summary of Pathology Expenditure - 2019/20



### Summary of Pathology Expenditure - 2018/19



## LS&D funding (total allocation) spent per non-commercial participant

This chart summarises the non-commercial participant spend, by NHS organisations from 2018/19 to 2019/20.

It also shows the average All Wales cost per patient for each FY (indicated by Red line) and the England cost per participant (indicated by yellow line).

### Note:


The figures for Wales have been calculated using the total Local, Support and Delivery funding.

The English average per participant figure is the total NIHR CRN and Research Capability Funding allocations measured against overall recruitment, as specific funding detail in England is not available

### Source:

2018/19, 2019/20 Annual Returns

2018/19, 2019/20 Performance Data



# Delivery funding spent per non- commercial participant

This chart summarises the non-commercial participant spend, by NHS organisations from 2018/19 to 2019/20.

It also shows the average All Wales cost per patient for each FY (indicated by Red line) and the England cost per participant (indicated by yellow line).

## Note:


The figures for Wales have been calculated using the Delivery funding only.

The English average per participant figure is the total NIHR CRN and Research Capability Funding allocations measured against overall recruitment, as specific funding detail in England is not available

## Source:

2018/19, 2019/20 Annual Returns

2018/19, 2019/20 Performance Data



## Cost per patient recruited - weighted

This chart summarises the non-commercial participant spend, by NHS organisations from 2018/19 to 2019/20.

This is calculated by comparing the weighted recruitment against the Delivery funding amount.

It also shows the same data for the Wales cost per patient for each FY (indicated by Red line) and the England cost per participant (indicated by yellow line).

Note:


The figures for Wales have been calculated using the Delivery funding and recruitment figures split by study complexity.

The English average per participant figure is the total NIHR CRN and Research Capability Funding allocations measured against overall recruitment, as specific funding detail in England is not available

Source:

2018/19, 2019/20 Annual Returns

2018/19, 2019/20 Performance Data




## Weighted recruitment spend against delivery funding - compared to All-Wales average

In this chart, where the figure =1, this equates to the average All Wales spend per recruited participant.

Where the figures >= 1, this equates to a higher than the average All Wales spend per recruited participant.

Where the figures <= 1, this equates to a lower than the average All Wales spend per recruited participant

Source:  
2018/19, 2019/20 Annual Returns



# Cost Recovery


This chart summarises the proportion of cost recovery by NHS organisations from 2018/19 to 2019/20.

Note:

This chart shows the amount of cost recovery reported in the Local Support and Delivery Annual Returns, as a percentage of overall Funding Allocation

Source:

2018/19, 2019/20 Annual Returns



## All Wales spend on research delivery by pay band


This chart summarises the amount of All Wales spend across pay bands in research delivery from 2018/19 to 2019/20.

### Note:

Expenditure by pay band of posts categorised as 'Delivery', as reported in the Local Support and Delivery Annual Returns

### Source:

2018/19, 2019/20 Annual Returns





## Proportion of spend on research delivery by pay band


This chart summarises the proportion of spend across pay bands in research delivery by NHS organisation from 2018/19 to 2019/20.

### Note:

Distribution of expenditure by pay band of posts categorised as 'Delivery', as reported in the Local Support and Delivery Annual Returns

### Source:

2018/19, 2019/20 Annual Returns



# Research performance in NHS Wales – 2019/20

Business Intelligence Report  
Version 1.0  
31st July 2020

## How to use this business intelligence report (1)

This slide is part of the explanatory notes for the Research performance in NHS Wales – 2019/20 (Business Intelligence Report).

These notes are to be used in conjunction with the following slides


### Business Intelligence report – slide layout

**Title:** concisely describes the data or information being conveyed.

**Explanation:** describes the data or information being conveyed in more detail than the title.

This may include items of note or caveats to explain the reasons for inclusion or exclusion of certain data or information.

**Data source:** describes the data or information source used to obtain data for interrogation or manipulation.



**Visual representation:** a visual (graphical or tabular) representation of the data following interrogation or manipulation.

Note: Any additional information included with the visual representation is intended to further explain the visual.

## How to use this business intelligence report (2)

This slide is part of the explanatory notes for the Research performance in NHS Wales – 2019/20 (Business Intelligence Report).

These notes are to be used in conjunction with the following slides

### NHS Organisations

The NHS organisation names used in this report are those up to 31 Mar 2019. Where the organisation names are abbreviated, they are usually abbreviated as follows:

	NHS Organisation
AB	Aneurin Bevan University Health Board
BC	Betsi Cadwaladr University Health Board
CV	Cardiff and Vale University Health Board
CTM	Cwm Taf Morgannwg University Health Board
HD	Hywel Dda University Health Board
PT	Powys Teaching Health Board
PHW	Public Health Wales
SB	Swansea Bay University Health Board
VNHST	Velindre University NHS Trust
WAST	Welsh Ambulance Services NHS Trust

*NB: On 1st April 2019, responsibilities for healthcare services in Bridgend County Borough Council transferred to Cwm Taf University Health Board. To reflect the new boundary changes the health board names were also changed to Cwm Taf Morgannwg UHB and Swansea Bay UHB. This is reflected in the 2019/20 data. Note that any data for the NHS organisation for 2018/19 will be based on the boundaries pre-2019.*

### Primary Care Research Incentive Scheme (PiCRIS)

The PiCRIS financial award for GP practices is dependent

Funding Level			Peer support to other practices
	≥ 2 studies	≥ 5 studies	
Level 2+		✓	✓
Level 2		✓	
Level 1	✓		
Affiliate	No set study delivery target. Practices can access PiCRIS benefits. No financial award.		

### Research Directory

The following Health and Care Research Wales Directory categories are used in the report.

Classification	Definition
Portfolio	Non commercial High-quality, non-commercial research studies that meet defined eligibility criteria for: - Source of funding; - Open competition; and - High quality peer review.
	Commercial Commercial contract research studies that are industry funded and industry sponsored.
Non-Portfolio	 Research studies that do not meet the portfolio eligibility criteria. This includes 'Pathway to Portfolio'.
	Pathway to Portfolio Research studies with Health and Care Research Wales funded activities undertaken to inform the development of a portfolio study or a grant application for a portfolio study.

### Site identification

The site identification service enables sponsors (or authorised delegates) to gather expressions of interest (EoI) from the NHS in research opportunities. NHS organisations and GP practices can be notified of research opportunities express and interest in participating.

# How to use this business intelligence report (2)

This slide is part of the explanatory notes for the Research performance in NHS Wales – 2019/20 (Business Intelligence Report).

These notes are to be used in conjunction with the following slides

## Specialty

Researchers must assign their studies to one of thirty managing specialties, which is the disease area most relevant to the study. In England, the managing specialty may be selected depending on where the study is being delivered, for example a diabetes study may be mapped to Primary Care if GPs are recruiting participants. Supporting specialties are selected by the researcher to confirm any other relevant disease area. This is why in Wales, much of our reporting is focused on all specialties, rather than solely on managing specialty.

## Adjustments

Data adjustment has been performed to allow appropriate comparisons of research activity in Wales to specific organisations or similar areas in England, These adjustments have been based on population size.

Comparative benchmarking has been completed against the NIHR Local Clinical Research Networks (LCRNs) of Greater Manchester and of North East & North Cumbria. These have been used as comparators as they have a similar population to Wales, and North East & North Cumbria is similar in rurality to Wales.

Additional benchmarking against specific NHS England organisations has been included where identified by NHS organisations in Wales.

Note: No comparable organisation was identified for Public Health Wales, so this has not been included.

## Research Study Categories

The following complexity band have been used when categorising research studies. These bands differentiate between study complexity and their associated costs.

Complexity band	Definition
Interventional studies	A study where the participants' exposure to a particular intervention (e.g. care pathway or lifestyle) is influenced by participating in the study (e.g. whether or not a participant receives a particular treatment will be determined by the research protocol).
Observational studies	A study in which the participants' lifestyle or care pathway is not affected by being part of the study (e.g. the investigator does not determine whether or not participants receive or do not receive a particular treatment).
Large sample studies	A study where the total UK planned sample size (throughout the lifetime of the study), is equal to, or greater than 10,000 participants. This can be an observational or interventional study, but the key factor to determine the band is the total planned sample (participant) size of the study.
Commercial studies	Commercial contract research studies that are industry funded and industry sponsored.

## How to use this business intelligence report (4)

This slide is part of the explanatory notes for the Research performance in NHS Wales – 2019/20 (Business Intelligence Report).

These notes are to be used in conjunction with the following slides

### Performance against key indicators

Performance against key indicators is calculated and rated as follows:

#### Open to recruitment studies:

RAG Rating = % recruitment – % time elapsed

% recruitment =  $\frac{\text{Actual recruitment total}}{\text{Target recruitment}}$

% time elapsed =  $\frac{\text{Number of days open}}{\text{Number of days planned open}}$

Note: (Number of days open = End date of reporting period – Actual opening date)  
(Number of days planned open = Planned closure to recruitment date – Actual opening date)

RAG ratings for open to recruitment studies:

Rating	Definition
RED	% recruitment is 30% behind the % time elapsed (e.g.: RAG Rating = -30% or less)
AMBER	% recruitment is up to and including 30% behind % time elapsed (e.g.: RAG Rating = $\leq -1\%$ $\geq -29\%$ )
GREEN	% recruitment is equal to or is greater than % time elapsed (e.g.: RAG Rating = $\geq 0\%$ )

### Closed to recruitment studies:

RAG Rating = % recruitment

% recruitment =  $\frac{\text{Actual recruitment total}}{\text{Target recruitment}}$

RAG ratings for closed to recruitment studies:

Rating	Definition
RED	% recruitment is < 100%
GREEN	% recruitment $\geq 100\%$

### Excluded data:

The excluded data or studies include:

Rating	Definition
BLACK	<ul style="list-style-type: none"> <li>Primary care studies – Due to the variation in approaches taken by NHS organisation in planning study recruitment targets, Welsh Government have decided that primary care studies will be excluded for now.</li> <li>Any studies that have not been open to recruitment within the time period of report (including any studies that have been withdrawn/suspended).</li> <li>PIC studies.</li> <li>Any studies missing accurate data that is required to evaluate performance as above.</li> </ul>

# Contents

1. Research opportunities provided to NHS patients / service users in Wales
2. How we compare
3. Promoting Wales: responding to and attracting Sponsors to Wales to increase research in Wales for patient benefit
4. Welsh led research
5. Research delivery performance in Wales

# Section 1

## Research opportunities provided to NHS patients / service users in Wales

This section includes:

- An overall snapshot of the research activity and performance for 2019/20
- An overview of the research opportunities provided in 2018/19
- A comparison with the other UK nations in terms of opportunities provided to their patients and service users
- Proportion of studies that have been set up and have recruited participants against those that have not recruited participants yet
- Insight into some of the most prevalent diseases in Wales and how much research activity is happening in these areas
- Detailed information on the numbers of studies mapped onto specialty areas

### Note:

- The activity data presented in this section includes both secondary care and primary care activity. However, primary care data is not included in any analysis related to delivery of studies to target due to lack of and inconsistency of target data.





**14,970** participants recruited in 2019/20



**219** active commercial studies

**616** active non-commercial studies



**6.0** per 1000 population recruited per annum (5-year average)



**56%** of commercial studies recruited first participant within 30 days

**66%** of non-commercial studies recruited first participant within 30 days



**218** studies open across more than one organisation

## Recruitment per 1000 population by NHS organisation

This chart shows the number of participants per 1000 population by health board in Wales, as an average over the last 5 years.

The line demonstrating the 5-year Wales average includes all NHS organisations (health boards and trusts).


Note: This includes both non-commercial and commercial study recruitment.

The population data for Cwm Taf Morgannwg UHB & Swansea Bay UHB has been adjusted for this report to reflect the boundary change in 2019.

Source:

NIHR Open Data Platform


ONS Population Data



# Number of open studies by NHS organisation and proportion that have recruited

This chart shows a comparison of the number of studies that NHS organisations set up to recruit participants by financial year and the proportion of those studies that have recruited participants.

The majority of organisations have increased the number of open studies although the proportion of recruiting studies is variable.



Source: NHS Research Performance Reports – Non-commercial and Commercial activity

## Disease prevalence compared to the number of patients recruited into relevant research studies

This data compares recruitment activity against some of the prevalent disease areas in Wales.

Each disease area has two map images:

- The map on the left shows recruitment activity over the last 5 years.
- The map on right shows disease prevalence

The darker the colour, the more recruitment there has been / prevalent a disease is.

Note: Prevalence data is taken from the Quality and Outcomes Framework disease registers and so is limited to the conditions that are tracked by the framework.

Wales disease prevalence data has not changed significantly since last year.


Source:

Wales ODP App – NIHR ODP

(<https://www.odp.nihr.ac.uk>)


Welsh Government Quality and Outcomes Framework Statistics 2018/19

### Obesity




The above chart shows there is low research activity in the areas where obesity is at its most prevalent.

### Diabetes (Type 1 & Type 2)




The above chart shows there is high prevalence of diabetes in Wales with varying levels of research activity

### Asthma



The above chart shows there is low research activity in the areas where asthma is at its most prevalent.

### Cancer



The above chart shows that research activity generally meets the prevalence of cancer, but this is not Wales-wide.

## Number of studies (non-commercial portfolio and commercial) open and recruiting, by NHS organisation

This chart shows the number of studies (non-commercial portfolio and commercial) open and recruiting by NHS organisation. The last column shows that there was an overall decrease from the previous year. Critical care and mental health studies increased from last year.

This contains studies with a managing or supporting specialty, so the same study could appear more than once.

**Note:** Blue cells indicate where the speciality maps to Welsh Government disease delivery areas.

Source:

2018/19 and 2019/20 performance reports

	AB UHB	BC UHB	CTM UHB	CV UHB	HD UHB	PHW	PTHB	SB UHB	VNHST	WAST	Grand Total	All Wales change from 18/19
Ageing	4	0	0	4	0	0	0	1	0	0	7	-5
Anaesthesia, Perioperative Medicine	4	3	3	5	1	0	0	2	0	0	12	+3
Cancer	22	30	16	50	17	0	1	38	63	0	158	-2
Cardiovascular Disease	8	4	5	17	1	0	0	11	1	0	31	+2
Children	6	5	8	28	4	1	0	8	0	0	35	-9
Critical Care	8	1	6	12	2	0	0	6	0	0	20	+9
Dementias And Neurodegeneration	8	7	5	15	5	0	0	4	0	0	30	+5
Dermatology	8	2	1	6	0	0	0	1	0	0	12	0
Diabetes	0	2	2	14	0	0	0	6	0	0	17	+2
Ear, Nose And Throat	2	1	0	3	0	0	0	1	0	0	4	-1
Gastroenterology	4	0	0	8	1	0	0	5	0	0	15	+6
Genetics	4	3	3	11	4	0	0	5	1	0	18	-5
Haematology	2	2	1	11	0	0	0	2	0	0	14	-2
Health Services And Delivery Research	4	4	1	6	3	0	1	1	0	1	12	-8
Hepatology	2	1	1	4	1	0	0	6	0	0	11	-1
Infection	3	1	6	9	3	1	0	5	0	0	14	-1
Injuries And Emergencies	5	6	3	14	3	0	0	8	0	3	20	-6
Mental Health	7	5	7	11	4	0	3	4	0	0	24	+10
Metabolic And Endocrine Disorders	1	2	2	4	0	0	0	1	0	0	8	0
Musculoskeletal Disorders	6	3	4	16	3	0	0	4	0	0	23	-9
Neurological Disorders	3	2	2	10	1	0	0	10	0	0	17	-11
Ophthalmology	0	0	1	3	0	0	0	0	0	0	4	0
Oral And Dental Health	1	0	1	2	0	0	0	0	0	0	3	0
Primary Care	10	13	14	17	6	0	1	9	0	1	35	-8
Public Health	1	1	0	2	0	1	0	1	0	1	4	-8
Renal Disorders	3	5	2	19	0	0	0	8	0	0	29	-1
Reproductive Health And Childbirth	5	4	2	12	1	0	0	10	0	0	20	-8
Respiratory Disorders	8	5	4	13	10	0	0	5	0	0	27	-2
Stroke	6	5	1	8	3	0	0	11	0	0	17	-2
Surgery	16	12	5	26	6	0	0	15	2	0	51	0
<b>Grand Total</b>	<b>103</b>	<b>87</b>	<b>72</b>	<b>255</b>	<b>49</b>	<b>2</b>	<b>4</b>	<b>137</b>	<b>63</b>	<b>3</b>	<b>523</b>	<b>-11</b>

## Number of non-commercial portfolio studies open and recruiting, by NHS organisation

This chart shows the number of **non-commercial** portfolio studies open and recruiting by NHS organisation. The last column shows was an overall decrease from the previous year. Critical care and mental health studies increased from last year.

This contains studies with a managing or supporting specialty, so the same study could appear more than once.

**Note:** Blue cells indicate where the specialty maps to Welsh Government disease delivery areas.

Source:

2018/19 and 2019/20 performance reports

Row Labels	AB UHB	BC UHB	CTM UHB	CV UHB	HD UHB	PHW	PTHB	SB UHB	VNHST	WAST	Grand Total	All Wales change from 18/19
Ageing	4	0	0	4	0	0	0	1	0	0	7	-3
Anaesthesia, Perioperative Medicine	4	3	3	5	1	0	0	2	0	0	12	+3
Cancer	21	30	16	40	16	0	1	30	48	0	124	-3
Cardiovascular Disease	5	2	4	8	1	0	0	6	1	0	16	+3
Children	6	5	8	27	4	1	0	8	0	0	34	-4
Critical Care	8	1	6	12	2	0	0	6	0	0	20	+9
Dementias And Neurodegeneration	8	6	5	12	5	0	0	4	0	0	26	+4
Dermatology	6	2	1	6	0	0	0	1	0	0	10	+1
Diabetes	0	2	1	11	0	0	0	2	0	0	11	+2
Ear, Nose And Throat	2	1	0	3	0	0	0	1	0	0	4	-1
Gastroenterology	2	0	0	8	1	0	0	2	0	0	10	+3
Genetics	4	3	3	11	4	0	0	5	1	0	18	-4
Haematology	1	2	1	7	0	0	0	2	0	0	9	0
Health Services And Delivery Research	4	4	1	6	3	0	1	1	0	1	12	-7
Hepatology	2	1	1	4	1	0	0	5	0	0	10	+2
Infection	3	1	6	8	3	1	0	5	0	0	13	-2
Injuries And Emergencies	5	6	3	14	3	0	0	8	0	3	20	-1
Mental Health	7	5	7	11	3	0	3	4	0	0	23	+10
Metabolic And Endocrine Disorders	1	1	2	3	0	0	0	0	0	0	6	+2
Musculoskeletal Disorders	6	3	4	13	3	0	0	4	0	0	20	-6
Neurological Disorders	3	2	2	9	1	0	0	5	0	0	12	-3
Ophthalmology	0	0	1	2	0	0	0	0	0	0	3	+1
Oral And Dental Health	1	0	1	2	0	0	0	0	0	0	3	0
Primary Care	9	12	11	16	5	0	1	8	0	1	30	-7
Public Health	1	1	0	2	0	1	0	1	0	1	4	-8
Renal Disorders	3	5	2	15	0	0	0	4	0	0	21	-1
Reproductive Health And Childbirth	5	4	2	12	1	0	0	10	0	0	20	-7
Respiratory Disorders	8	5	4	9	9	0	0	5	0	0	22	-1
Stroke	5	4	1	7	3	0	0	11	0	0	15	-4
Surgery	14	12	5	22	6	0	0	15	2	0	46	+1
<b>Grand Total</b>	<b>88</b>	<b>81</b>	<b>65</b>	<b>199</b>	<b>43</b>	<b>2</b>	<b>4</b>	<b>101</b>	<b>48</b>	<b>3</b>	<b>397</b>	<b>-20</b>



## Number of commercial studies open and recruiting, by NHS organisation

This chart shows the number of **commercial** studies open and recruiting by NHS organisation. The last column shows that there was an overall increase in the number of commercial studies. Neurological disorders showed the biggest drop from the previous year.

This contains studies with a managing or supporting specialty, so the same study could appear more than once.

**Note:** Blue cells indicate where the speciality maps to Welsh Government disease delivery areas.

Source:

2018/19 and 2019/20 performance reports

	AB UHB	BC UHB	CTM UHB	CV UHB	HD UHB	PHW	PTHB	SB UHB	VNHST	WAST	Grand Total	All Wales change from 18/19
Ageing	0	0	0	0	0	0	0	0	0	0	0	-2
Anaesthesia, Perioperative Medicine	0	0	0	0	0	0	0	0	0	0	0	0
Cancer	1	0	0	10	1	0	0	8	15	0	34	+1
Cardiovascular Disease	3	2	1	9	0	0	0	5	0	0	15	-1
Children	0	0	0	1	0	0	0	0	0	0	1	-5
Critical Care	0	0	0	0	0	0	0	0	0	0	0	0
Dementias And Neurodegeneration	0	1	0	3	0	0	0	0	0	0	4	+1
Dermatology	2	0	0	0	0	0	0	0	0	0	2	-1
Diabetes	0	0	1	3	0	0	0	4	0	0	6	0
Ear, Nose And Throat	0	0	0	0	0	0	0	0	0	0	0	0
Gastroenterology	2	0	0	0	0	0	0	3	0	0	5	+3
Genetics	0	0	0	0	0	0	0	0	0	0	0	-1
Haematology	1	0	0	4	0	0	0	0	0	0	5	-2
Health Services And Delivery Research	0	0	0	0	0	0	0	0	0	0	0	-1
Hepatology	0	0	0	0	0	0	0	1	0	0	1	-3
Infection	0	0	0	1	0	0	0	0	0	0	1	+1
Injuries And Emergencies	0	0	0	0	0	0	0	0	0	0	0	-5
Mental Health	0	0	0	0	1	0	0	0	0	0	1	0
Metabolic And Endocrine Disorders	0	1	0	1	0	0	0	1	0	0	2	-2
Musculoskeletal Disorders	0	0	0	3	0	0	0	0	0	0	3	-3
Neurological Disorders	0	0	0	1	0	0	0	5	0	0	5	-8
Ophthalmology	0	0	0	1	0	0	0	0	0	0	1	-1
Oral And Dental Health	0	0	0	0	0	0	0	0	0	0	0	0
Primary Care	1	1	3	1	1	0	0	1	0	0	5	-1
Public Health	0	0	0	0	0	0	0	0	0	0	0	0
Renal Disorders	0	0	0	4	0	0	0	4	0	0	8	0
Reproductive Health And Childbirth	0	0	0	0	0	0	0	0	0	0	0	-1
Respiratory Disorders	0	0	0	4	1	0	0	0	0	0	5	-1
Stroke	1	1	0	1	0	0	0	0	0	0	2	+2
Surgery	2	0	0	4	0	0	0	0	0	0	5	-1
<b>Grand Total</b>	<b>15</b>	<b>6</b>	<b>7</b>	<b>56</b>	<b>6</b>	<b>0</b>	<b>0</b>	<b>36</b>	<b>15</b>	<b>0</b>	<b>126</b>	<b>+9</b>

## Number of studies in Wales by sponsorship status

This chart shows the number of studies in Wales by sponsorship status (non-commercial or commercial), in order to easily compare this activity for any of the specialty areas.

This contains studies with a managing or supporting specialty, so the same study could appear more than once.

Note: Blue cells indicate where the speciality maps to Welsh Government disease delivery areas.

Source:

2018/19 and 2019/20 performance reports

	Commercial	Change	Non-commercial	Change	Total	Change
Ageing	0	-2	7	-3	7	-5
Anaesthesia, Perioperative Medicine And Pain Management	0	0	12	+3	12	+3
Cancer	34	+1	124	-3	158	-2
Cardiovascular Disease	16	0	16	+3	32	+3
Children	1	-5	34	-4	35	-9
Critical Care	0	0	20	+9	20	+9
Dementias And Neurodegeneration	4	+1	26	+4	30	+5
Dermatology	2	-1	10	+1	12	0
Diabetes	6	0	11	+2	17	+2
Ear, Nose And Throat	0	0	4	-1	4	-1
Gastroenterology	5	+3	10	+3	15	+6
Genetics	0	-1	18	-4	18	-5
Haematology	5	-2	9	0	14	-2
Health Services And Delivery Research	0	-1	13	-6	13	-7
Hepatology	1	-3	10	+2	11	-1
Infection	1	+1	13	-2	14	-1
Injuries And Emergencies	0	-5	20	-1	20	-6
Mental Health	1	0	23	+10	24	+10
Metabolic And Endocrine Disorders	2	-2	6	+2	8	0
Musculoskeletal Disorders	3	-3	20	-6	23	-9
Neurological Disorders	5	-8	12	-3	17	-11
Ophthalmology	1	-1	3	+1	4	0
Oral And Dental Health	0	0	3	0	3	0
Primary Care	5	-1	30	-7	35	-8
Public Health	0	0	4	-8	4	-8
Renal Disorders	8	0	21	-1	29	-1
Reproductive Health And Childbirth	0	-1	20	-7	20	-8
Respiratory Disorders	5	-1	22	-1	27	-2
Stroke	2	+2	15	-4	17	-2
Surgery	5	-1	46	+1	51	0
<b>Grand Total (Excluding duplicates)</b>	127	+10	398	-19	525	-9



## Recruitment to non-commercial portfolio and commercial studies, by NHS organisation

This chart shows the amount of recruitment to non-commercial portfolio and commercial studies, by NHS organisation. The last column shows that there was a significant decrease in recruitment overall from the previous year.

This contains studies with a managing or supporting specialty, so recruitment to a study could appear more than once.

**Note:** Blue cells indicate where the speciality maps to Welsh Government disease delivery areas.

Source:

2018/19 and 2019/20 performance reports

	AB UHB	BC UHB	CTM UHB	CV UHB	HD UHB	PHW	PTHB	SB UHB	VNHST	WAST	All Wales (Duplicated Removed)	All Wales change from 18/19
Ageing	14	0	0	82	0	0	0	6	0	0	102	-117
Anaesthesia, Perioperative Medicine	91	65	264	329	4	0	0	55	0	0	808	-669
Cancer	404	543	148	457	480	0	2	431	534	0	2999	-354
Cardiovascular Disease	99	106	76	337	11	0	0	163	3	0	795	+485
Children	30	34	69	480	132	368	0	82	0	0	1195	-1477
Critical Care	169	54	282	460	19	0	0	101	0	0	1085	+541
Dementias And Neurodegeneration	65	75	30	83	20	0	0	28	0	0	301	-269
Dermatology	143	24	4	123	0	0	0	2	0	0	296	-397
Diabetes	0	7	41	106	0	0	0	24	0	0	178	-23
Ear, Nose And Throat	8	2	0	15	0	0	0	2	0	0	27	-74
Gastroenterology	14	0	0	63	94	0	0	26	0	0	197	+99
Genetics	14	6	10	91	53	0	0	47	1	0	222	-961
Haematology	46	82	1	75	0	0	0	10	0	0	214	+43
Health Services And Delivery Research	38	103	1	154	35	0	1	1	0	4	337	+23
Hepatology	22	1	3	83	10	0	0	14	0	0	133	+67
Infection	84	113	318	290	83	368	0	95	0	0	1351	-2008
Injuries And Emergencies	146	38	5	561	22	0	0	280	0	238	1290	+246
Mental Health	306	113	332	198	52	0	8	52	0	0	1061	+269
Metabolic And Endocrine Disorders	3	16	283	39	0	0	0	5	0	0	346	-1263
Musculoskeletal Disorders	70	102	11	449	14	0	0	172	0	0	818	-116
Neurological Disorders	13	47	8	430	4	0	0	48	0	0	550	-39
Ophthalmology	0	0	1	36	0	0	0	0	0	0	37	-81
Oral And Dental Health	20	0	35	165	0	0	0	0	0	0	220	-208
Primary Care	210	275	134	129	56	0	2	48	0	4	858	-347
Public Health	27	5	0	124	0	68	0	5	0	217	446	-1573
Renal Disorders	41	28	18	334	0	0	0	58	0	0	479	-422
Reproductive Health And Childbirth	68	30	9	1402	1	0	0	203	0	0	1713	-40
Respiratory Disorders	108	464	50	305	182	0	0	38	0	0	1147	+98
Stroke	92	75	4	111	82	0	0	141	0	0	505	-5
Surgery	258	145	255	938	43	0	0	462	4	0	2105	+933
<b>Grand Total (Excluding duplicates)</b>	<b>1729</b>	<b>1992</b>	<b>1702</b>	<b>5655</b>	<b>981</b>	<b>436</b>	<b>10</b>	<b>1693</b>	<b>534</b>	<b>238</b>	<b>14970</b>	<b>-5909</b>

## Recruitment to non-commercial portfolio studies by NHS organisation

This chart shows the amount recruitment to non-commercial portfolio studies by NHS organisation. The last column shows that there was a significant decrease in recruitment overall from the previous year.

This contains studies with a managing or supporting specialty, so recruitment to a study could appear more than once.

**Note:** Blue cells indicate where the specialty maps to Welsh Government disease delivery areas.

Source:

2018/19 and 2019/20 performance reports

	AB UHB	BC UHB	CTM UHB	CV UHB	HD UHB	PHW	PTHB	SB UHB	VNHST	WAST	All Wales (Duplic ates Remove d)	All Wales change from 18/19
Ageing	14	0	0	82	0	0	0	6	0	0	102	-94
Anaesthesia, Perioperative Medicine	91	65	264	329	4	0	0	55	0	0	808	-669
Cancer	403	543	148	432	479	0	2	397	489	0	2893	-375
Cardiovascular Disease	60	87	69	209	11	0	0	104	3	0	543	+376
Children	30	34	69	477	132	368	0	82	0	0	1192	-1468
Critical Care	169	54	282	460	19	0	0	101	0	0	1085	+541
Dementias And Neurodegeneration	65	47	30	77	20	0	0	28	0	0	267	-294
Dermatology	137	24	4	123	0	0	0	2	0	0	290	-391
Diabetes	0	7	39	95	0	0	0	5	0	0	146	+3
Ear, Nose And Throat	8	2	0	15	0	0	0	2	0	0	27	-74
Gastroenterology	8	0	0	63	94	0	0	23	0	0	188	+117
Genetics	14	6	10	91	53	0	0	47	1	0	222	-960
Haematology	12	82	1	67	0	0	0	10	0	0	172	+14
Health Services And Delivery Research	38	103	1	154	35	0	1	1	0	4	337	+25
Hepatology	22	1	3	83	10	0	0	13	0	0	132	+70
Infection	84	113	318	279	83	368	0	95	0	0	1340	-2019
Injuries And Emergencies	146	38	5	561	22	0	0	280	0	238	1290	+365
Mental Health	306	113	332	198	48	0	8	52	0	0	1057	+267
Metabolic And Endocrine Disorders	3	8	283	25	0	0	0	0	0	0	319	-1279
Musculoskeletal Disorders	70	102	11	434	14	0	0	172	0	0	803	-77
Neurological Disorders	13	47	8	429	4	0	0	39	0	0	540	-22
Ophthalmology	0	0	1	32	0	0	0	0	0	0	33	-80
Oral And Dental Health	20	0	35	165	0	0	0	0	0	0	220	-208
Primary Care	208	264	124	122	53	0	2	37	0	4	814	-122
Public Health	27	5	0	124	0	68	0	5	0	217	446	-1573
Renal Disorders	41	28	18	320	0	0	0	50	0	0	457	-405
Reproductive Health And Childbirth	68	30	9	1402	1	0	0	203	0	0	1713	+61
Respiratory Disorders	108	464	50	295	179	0	0	38	0	0	1134	+112
Stroke	58	67	4	97	82	0	0	141	0	0	449	-61
Surgery	246	145	255	916	43	0	0	462	4	0	2071	+942
<b>Grand Total (Excluding duplicates)</b>	<b>1519</b>	<b>1931</b>	<b>1674</b>	<b>5386</b>	<b>961</b>	<b>436</b>	<b>10</b>	<b>1488</b>	<b>489</b>	<b>238</b>	<b>14132</b>	<b>-5786</b>

## Recruitment to commercial studies by NHS organisation

This chart shows the amount of recruitment to commercial studies by NHS organisation. The last column shows there was a slight decrease in recruitment from the previous year.

This contains studies with a managing or supporting specialty, so recruitment to a study could appear more than once.

**Note:** Blue cells indicate where the speciality maps to Welsh Government disease delivery areas.

Source:

2018/19 and 2019/20 performance reports

	AB UHB	BC UHB	CTM UHB	CV UHB	HD UHB	PHW	PTHB	SB UHB	VNHST	WAST	All Wales (Duplic ates Remov ed)	All Wales change from 18/19
Ageing	0	0	0	0	0	0	0	0	0	0	0	-23
Anaesthesia, Perioperative Medicine	0	0	0	0	0	0	0	0	0	0	0	0
Cancer	1	0	0	25	1	0	0	34	45	0	106	+21
Cardiovascular Disease	39	19	7	128	0	0	0	59	0	0	252	+109
Children	0	0	0	3	0	0	0	0	0	0	3	-9
Critical Care	0	0	0	0	0	0	0	0	0	0	0	0
Dementias And Neurodegeneration	0	28	0	6	0	0	0	0	0	0	34	+25
Dermatology	6	0	0	0	0	0	0	0	0	0	6	-6
Diabetes	0	0	2	11	0	0	0	19	0	0	32	-26
Ear, Nose And Throat	0	0	0	0	0	0	0	0	0	0	0	0
Gastroenterology	6	0	0	0	0	0	0	3	0	0	9	-18
Genetics	0	0	0	0	0	0	0	0	0	0	0	-1
Haematology	34	0	0	8	0	0	0	0	0	0	42	+29
Health Services And Delivery Research	0	0	0	0	0	0	0	0	0	0	0	-2
Hepatology	0	0	0	0	0	0	0	1	0	0	1	-3
Infection	0	0	0	11	0	0	0	0	0	0	11	+11
Injuries And Emergencies	0	0	0	0	0	0	0	0	0	0	0	-119
Mental Health	0	0	0	0	4	0	0	0	0	0	4	+2
Metabolic And Endocrine Disorders	0	8	0	14	0	0	0	5	0	0	27	+16
Musculoskeletal Disorders	0	0	0	15	0	0	0	0	0	0	15	-39
Neurological Disorders	0	0	0	1	0	0	0	9	0	0	10	-17
Ophthalmology	0	0	0	4	0	0	0	0	0	0	4	-1
Oral And Dental Health	0	0	0	0	0	0	0	0	0	0	0	0
Primary Care	2	11	10	7	3	0	0	11	0	0	44	-225
Public Health	0	0	0	0	0	0	0	0	0	0	0	0
Renal Disorders	0	0	0	14	0	0	0	8	0	0	22	-17
Reproductive Health And Childbirth	0	0	0	0	0	0	0	0	0	0	0	-101
Respiratory Disorders	0	0	0	10	3	0	0	0	0	0	13	-14
Stroke	34	8	0	14	0	0	0	0	0	0	56	+56
Surgery	12	0	0	22	0	0	0	0	0	0	34	-9
<b>Grand Total (Excluding duplicates)</b>	<b>210</b>	<b>61</b>	<b>28</b>	<b>269</b>	<b>20</b>	<b>0</b>	<b>0</b>	<b>205</b>	<b>45</b>	<b>0</b>	<b>838</b>	<b>-123</b>

## Recruitment to studies in Wales by sponsorship status

This chart shows the amount of recruitment to studies in Wales by sponsorship status (non-commercial or commercial), in order to easily compare this activity for any of the specialty areas.

This contains studies with a managing or supporting specialty, so recruitment to a study could appear more than once.

**Note:** Blue cells indicate where the speciality maps to Welsh Government disease delivery areas.

Source:

2018/19 and 2019/20 performance reports

	Commercial		Non-commercial		Total	
		Change		Change		Change
Ageing	0	-23	102	-94	102	-117
Anaesthesia, perioperative medicine and pain management	0	0	808	-669	808	-669
Cancer	106	+21	2893	-375	2999	-354
Cardiovascular disease	252	+109	543	+376	795	+485
Children	3	-9	1192	-1468	1195	-1477
Critical care	0	0	1085	+541	1085	+541
Dementias and neurodegeneration	34	+25	267	-294	301	-269
Dermatology	6	-6	290	-391	296	-397
Diabetes	32	-26	146	+3	178	-23
Ear, nose and throat	0	0	27	-74	27	-74
Gastroenterology	9	-18	188	+117	197	+99
Genetics	0	-1	222	-960	222	-961
Haematology	42	+29	172	+14	214	+43
Health Services Research	0	-2	337	+25	337	+23
Hepatology	1	-3	132	+70	133	+67
Infection	11	+11	1340	-2019	1351	-2008
Injuries and emergencies	0	-119	1290	+365	1290	+246
Mental Health	4	+2	1057	+267	1061	+269
Metabolic and endocrine disorders	27	+16	319	-1279	346	-1263
Musculoskeletal disorders	15	-39	803	-77	818	-116
Neurological disorders	10	-17	540	-22	550	-39
Ophthalmology	4	-1	33	-80	37	-81
Oral and dental health	0	0	220	-208	220	-208
Primary Care	44	-225	814	-122	858	-347
Public health	0	0	446	-1573	446	-1573
Renal disorders	22	-17	457	-405	479	-422
Reproductive Health	0	-101	1713	+61	1713	-40
Respiratory disorders	13	-14	1134	+112	1147	+98
Stroke	56	+56	449	-61	505	-5
Surgery	34	-9	2071	+942	2105	+933
<b>Grand Total (Excluding duplicates)</b>	<b>838</b>	<b>-123</b>	<b>14132</b>	<b>-5786</b>	<b>14970</b>	<b>-5909</b>

# Section 2

## How we compare

- This section shows how the research activity in Wales compares to specific organisations or similar areas in England.

### Note:

- All Wales research activity and individual NHS organisations have been benchmarked against the NIHR Local Clinical Research Networks (LCRNs) of Greater Manchester and of North East & North Cumbria. These have been used as comparators as they have a similar population to Wales, and North East & North Cumbria is similar in rurality to Wales.
- Additional benchmarking against specific NHS England organisations has been included where identified by NHS organisations in Wales.
- Target refers to the delivery framework targets for increasing numbers of studies (C1 & C2) and number of participants (D1 & D2)
- When comparisons have been made across areas, adjustments have been used to ensure comparability, based on population size
- *No comparable organisation was identified for Public Health Wales, so this has not been included in this section*

## Recruitment in Wales compared to other UK nations by study category


This chart shows the comparison of each NHS Wales organisation (adjusted) to each other. The graph on the right shows Wales' recruitment compared to the other UK nations by research study category.

The target refers to the recruitment target for commercial and non-commercial studies in the Delivery Framework (D1 & D2), which is based on the previous year's activity.


**Note:** The NHS Wales organisation values are pro-rata adjusted for comparison.

**Source:** CPMS Open Data Platform non-commercial and commercial activity.

Benchmarking recruitment in Wales 2015/16 - 2019/20 average by research study category



Benchmarking recruitment in UK Nations 2015/16 - 2019/20 average by research study category



# Number of studies in Wales compared to other UK nations by study category


This charts shows the comparison of each NHS Wales organisation (adjusted) to other UK nations by study category.

The target refers to the recruitment target for commercial and non-commercial studies in the Delivery Framework (C1 & C2), which is based on the previous year's activity.


Note: The NHS Wales organisation values are pro-rata adjusted for comparison.

Source: CPMS Open Data Platform non-commercial and commercial activity.

Benchmarking studies open & recruiting in Wales  
2015/16 - 2019/20 average by research study  
category



Benchmarking studies open & recruiting in UK Nations  
2015/16 - 2019/20 average  
by research study category





# Recruitment in Wales compared to similar areas in England

This chart shows a comparison of recruitment in Wales by study category and financial year.

This shows that Wales' recruitment is the lowest of the three similar areas.


The target refers to the recruitment target for commercial and non-commercial studies in the Delivery Framework (D1 & D2) , which is based on the previous year's activity.

Note: The data is benchmarked against the LCRNs of Greater Manchester and of North East & North Cumbria.

Greater Manchester had 1 large scale study that recruited 32K participants in 2018/19.

Source: CPMS Open Data Platform non-commercial and commercial activity.

Benchmarking recruitment in Wales 2015/16 - 2019/20 by research study category and financial year





# Number of studies in Wales compared to similar areas in England

This chart shows a comparison of all studies open and recruiting in Wales by study category and financial year.


This shows that Wales has far fewer studies open and recruiting compared to the two LCRNs.

The target refers to the recruitment target for commercial and non-commercial studies in the Delivery Framework (C1 & C2), which is based on the previous year's activity.

Note: The data is benchmarked against the NIHR CRNs of Greater Manchester and of North East & North Cumbria.

Source: CPMS Open Data Platform non-commercial and commercial activity.

Benchmarking studies open and recruiting in Wales 2015/16 - 2019/20 by research study category and financial year



## Recruitment at Aneurin Bevan UHB by study category and financial year


This chart shows recruitment to studies at Aneurin Bevan UHB by study category and financial year.

The target refers to the recruitment target for commercial and non commercial studies in the Delivery Framework (D1 & D2), which is based on the previous year's activity.

Note: The data is benchmarked against the LCRNs of Greater Manchester and of North East & North Cumbria (population adjusted to compare to the NHS organisation's population).

Source: CPMS Open Data Platform non-commercial and commercial activity.

Benchmarking recruitment in Aneurin Bevan 2015/16 - 2019/20 by research study category



## Studies open and recruiting at Aneurin Bevan UHB by study category and financial year


This chart shows a comparison of all studies open and recruiting Aneurin Bevan UHB by study category and financial year.

The target refers to the recruitment target for commercial and non commercial studies in the Delivery Framework (C1 & C2), which is based on the previous year's activity.

Note: The data is benchmarked against the LCRNs of Greater Manchester and of North East & North Cumbria (population adjusted to compare to the NHS organisation's population).

Source: CPMS Open Data Platform non-commercial and commercial activity.

Benchmarking studies open & recruiting in Aneurin Bevan 2015/16 - 2019/20 by research study category



## Recruitment at Betsi Cadwaladr UHB by study category and financial year

This chart shows recruitment to studies at Betsi Cadwaladr UHB by study category and financial year.


The target refers to the recruitment target for commercial and non-commercial studies in the Delivery Framework (D1 & D2), which is based on the previous year's activity.

Note: The data is benchmarked against Pennine Acute Hospitals NHS Trust, as well as the LCRNs of Greater Manchester and of North East & North Cumbria (population adjusted to compare to the NHS organisation's population).

One large scale study recruited 32K participants in Pennine Acute Hospital NHS Trust IN 2018/19.

Source: CPMS Open Data Platform non-commercial and commercial activity.

Benchmarking recruitment in Betsi Cadwaladr 2015/16 - 2019/20 by research study category



## Studies open and recruiting at Betsi Cadwaladr UHB by study category and financial year


This chart shows a comparison of all studies open and recruiting at Betsi Cadwaladr UHB by study category and financial year.

The target refers to the recruitment target for commercial and non-commercial studies in the Delivery Framework (C1 & C2), which is based on the previous year's activity.

Note: The data is benchmarked against Pennine Acute Hospitals NHS Trust, as well as the LCRNs of Greater Manchester and of North East & North Cumbria (population adjusted to compare to the NHS organisation's population).

Source: CPMS Open Data Platform non-commercial and commercial activity.

Benchmarking studies open & recruiting in Betsi Cadwaladr 2015/16 - 2019/20 by research study category



## Recruitment at Cardiff & Vale UHB by study category and financial year


This chart shows recruitment to studies at Cardiff & Vale UHB by study category and financial year.

The target refers to the recruitment target for commercial and non-commercial studies in the Delivery Framework (D1 & D2), which is based on the previous year's activity.

Note: The data is benchmarked against The Newcastle Upon Tyne Hospitals NHS Foundation Trust, as well as the LCRNs of Greater Manchester and of North East & North Cumbria (population adjusted to compare to the NHS organisation's population).

Source: CPMS Open Data Platform non-commercial and commercial activity.

Benchmarking recruitment in Cardiff & Vale 2015/16 - 2019/20 by research study category



## Studies open and recruiting at Cardiff & Vale UHB by study category and financial year


This chart shows a comparison of all studies open and recruiting Cardiff & Vale UHB by study category and financial year.

The target refers to the recruitment target for commercial and non-commercial studies in the Delivery Framework (C1 & C2), which is based on the previous year's activity.

**Note:** The data is benchmarked against The Newcastle Upon Tyne Hospitals NHS Foundation Trust, as well as the LCRNs of Greater Manchester and of North East & North Cumbria (population adjusted to compare to the NHS organisation's population).

**Source:** CPMS Open Data Platform non-commercial and commercial activity.

Benchmarking studies open & recruiting in Cardiff & Vale 2015/16 - 2019/20 by research study category



## Recruitment at Cwm Taf Morgannwg UHB by study category and financial year

This chart shows recruitment to studies at Cwm Taf Morgannwg UHB by study category and financial year.


The target refers to the recruitment target for commercial and non-commercial studies in the Delivery Framework (D1 & D2), which is based on the previous year's activity.

**Note:** The data is benchmarked against the LCRNs of Greater Manchester and of North East & North Cumbria (population adjusted to compare to the NHS organisation's population).

Target for 2019/20 adjusted to account for the boundary change to include Bridgend.

**Source:** CPMS Open Data Platform non-commercial and commercial activity.

Benchmarking recruitment in Cwm Taf 2015/16 - 2019/20 by research study category





## Studies open and recruiting at Cwm Taf Morgannwg UHB by study category and financial year

This chart shows a comparison of all studies open and recruiting at Cwm Taf Morgannwg UHB by study category and financial year.


The target refers to the recruitment target for commercial and non-commercial studies in the Delivery Framework (C1 & C2), which is based on the previous year's activity.

**Note:** The data is benchmarked against the LCRNs of Greater Manchester and of North East & North Cumbria (population adjusted to compare to the NHS organisation's population).

Target for 2019/20 adjusted to account for the boundary change to include Bridgend.

**Source:** CPMS Open Data Platform non-commercial and commercial activity.

Benchmarking studies open & recruiting in Cwm Taf 2015/16 - 2019/20 by research study category



# Recruitment at Hywel Dda UHB by study category and financial year


This chart shows recruitment to studies at Hywel Dda UHB by study category and financial year.

The target refers to the recruitment target for commercial and non-commercial studies in the Delivery Framework (D1 & D2), which is based on the previous year's activity.

Note: The data is benchmarked against the LCRNs of Greater Manchester and of North East & North Cumbria (population adjusted to compare to the NHS organisation's population).

Source: CPMS Open Data Platform non-commercial and commercial activity.

Benchmarking Recruitment in Hywel Dda 2015/16 - 2019/20 by research study category and Financial Year



## Studies open and recruiting at Hywel Dda UHB by study category and financial year


This chart shows a comparison of all studies open and recruiting Hywel Dda UHB by study category and financial year.

The target refers to the recruitment target for commercial and non-commercial studies in the Delivery Framework (C1 & C2), which is based on the previous year's activity.

**Note:** The data is benchmarked against the LCRNs of Greater Manchester and of North East & North Cumbria (population adjusted to compare to the NHS organisation's population).

**Source:** CPMS Open Data Platform non-commercial and commercial activity.

Benchmarking studies open & recruiting in Hywel Dda 2015/16 - 2019/20 by research study category




# Recruitment at Powys THB by study category and financial year

This chart shows recruitment to studies at Powys THB by study category and financial year.

The target refers to the recruitment target for commercial and non-commercial studies in the Delivery Framework (D1 & D2), which is based on the previous year's activity.

Note: The data is benchmarked against the LCRNs of Greater Manchester and of North East & North Cumbria (population adjusted to compare to the NHS organisation's population).

Source: CPMS Open Data Platform non-commercial and commercial activity.



## Studies open and recruiting at Powys THB by study category and financial year


This chart shows a comparison of all studies open and recruiting Powys THB by study category and financial year.

The target refers to the recruitment target for commercial and non-commercial studies in the Delivery Framework (C1 & C2), which is based on the previous year's activity.

**Note:** The data is benchmarked against the LCRNs of Greater Manchester and of North East & North Cumbria (population adjusted to compare to the NHS organisation's population).

**Source:** CPMS Open Data Platform non-commercial and commercial activity.

Benchmarking studies open & recruiting in Powys 2015/16 - 2019/20 by research study category



# Recruitment at Swansea Bay UHB by study category and financial year


This chart shows recruitment to studies at Swansea Bay UHB by study category and financial year.

The target refers to the recruitment target for commercial and non-commercial studies in the Delivery Framework (D1 & D2), which is based on the previous year's activity.

Note: The data is benchmarked against the LCRNs of Greater Manchester and of North East & North Cumbria (population adjusted to compare to the NHS organisation's population).

Source: CPMS Open Data Platform non-commercial and commercial activity.

Benchmarking recruitment in Swansea Bay 2015/16 - 2019/20 by research study category



# Studies open and recruiting at Swansea Bay UHB by study category and financial year


This chart shows a comparison of all studies open and recruiting Swansea Bay UHB by study category and financial year.

The target refers to the recruitment target for commercial and non-commercial studies in the Delivery Framework (C1 & C2), which is based on the previous year's activity.

Note: The data is benchmarked against the LCRNs of Greater Manchester and of North East & North Cumbria (population adjusted to compare to the NHS organisation's population).

Source: CPMS Open Data Platform non-commercial and commercial activity.

Benchmarking studies open & recruiting in Swansea Bay 2015/16 - 2019/20 by research study category



# Recruitment at Velindre University NHS Trust compared to a similar organisation in England


This chart shows recruitment to studies at Velindre University NHS Trust by study category and financial year.

The target refers to the recruitment target for commercial and non-commercial studies in the Delivery Framework (D1 & D2), which is based on the previous year's activity.

Note: The data is benchmarked against The Clatterbridge Cancer Centre NHS Foundation Trust.

Source: CPMS Open Data Platform non-commercial and commercial activity.

Benchmarking recruitment in Velindre 2015/16 - 2019/20 by research study category





## Number of studies at Velindre NHS University Trust compared to a similar organisation in England


This chart shows a comparison of all studies open and recruiting Velindre NHS University Trust by study category and financial year.

The target refers to the recruitment target for commercial and non-commercial studies in the Delivery Framework (C1 & C2), which is based on the previous year's activity.

Note: The data is benchmarked against The Clatterbridge Cancer Centre NHS Foundation Trust.

Source: CPMS Open Data Platform non-commercial and commercial activity.

Benchmarking studies open & recruiting in Velindre 2015/16 - 2019/20 by research study category




# Recruitment at Welsh Ambulance Services NHS Trust compared to ambulance services in England

This chart shows recruitment to studies at Welsh Ambulance Services NHS Trust by study category and financial year.

Note: The data is benchmarked against all NHS England Ambulance Service NHS Trusts.

Source: CPMS Open Data Platform non-commercial and commercial activity.




## Number of studies at Welsh Ambulance Services NHS Trust compared to ambulance services in England

This chart shows a comparison of all studies open and recruiting Welsh Ambulance Services NHS Trust by study category and financial year.

Note: The data is benchmarked against all NHS England Ambulance Service NHS Trusts.

Source: CPMS Open Data Platform non-commercial and commercial activity.

Studies open & recruiting 2015/16 - 2019/20 in the Welsh and English Ambulance Trusts by research study category



# Section 3

Promoting Wales: responding to and attracting Sponsors to Wales to increase research in Wales for patient benefit

This section includes:

- A comparison of the individual and collective performance of studies with more than one participating NHS organisation in Wales
- An analysis of the collective performance in Wales and how this compares against the UK study rating.
- Study setup analysis, including:
  - Timelines from confirmation that a site will be open for a study to Confirmation of capacity and capability
  - The time from confirmation of capacity and capability to the recruitment of first participant

## Combined performance of NHS organisations for studies with more than one participating organisation in Wales

This chart indicates the combined performance of NHS organisations against the combined target of all participating NHS Wales organisations where there is more than one participating organisation in Wales. This performance is also ranked against the whole UK performance for those studies.

The comparison against the UK wide study rating shows that three quarters of multisite studies are rated the same or better than the UK rating.


Note: Wales site performance contributes to the overall UK performance

Source: NHS Research Performance Reports – Non-commercial and commercial activity

CPMS Open Data Platform non-commercial and commercial activity.


**218** studies in Wales in 2019/20 were open in more than one NHS organisation (26%)

Individual Multi-site RAG Ratings




The chart to the left shows the RAG status' of each study-site based on each individual site's target and recruitment.

All Wales multi-site study performance vs UK rating



All Wales multi-site RAG ratings



The chart to the right calculates an All-Wales combined RAG status for each study and assigns it to each site for that study.

## Time to recruit the first participant after receipt of NHS local information


The top graph shows all studies, which includes studies where there may be very low target recruitment numbers, therefore a high number of days from confirmation of capacity and capability to first patient is expected.

The lower graph is only for studies with a target of at least 1 per month, where it would be reasonable to assume that recruitment of the first participant could take place within 30 days.


Note: The data only includes studies where the first participant was recruited in 2019/20.

Source: 2019/20 Performance report

### Median days to C&C and FPFV (All studies)



### Median days to C&C and FPFV (Target >12 recruits pa.)



# Section 4

## Welsh led research


This section includes:

- The number of non-commercial portfolio studies Sponsored by a Welsh organisation (NHS or University)
- The performance of sponsored research studies in Wales.
- The proportion of Welsh Chief Investigator led commercial studies in Wales.

# Sponsorship of non-commercial portfolio studies Welsh organisations,

This chart shows the distribution and number of non-commercial portfolio studies sponsored by Welsh organisations (NHS organisation or university) by financial year.

Cardiff University sponsors the highest number of studies by far compared to any other Sponsor in Wales.



Source:

2018/19 and 2019/20 Performance data

■ University Organisations ■ NHS Organisations




# Sponsor type for studies running in Wales

This chart shows the sponsor type for the studies running in Wales during 2019/20, by type of sponsoring organisation. The change from financial year 2018/19 is also shown.

**68%** of studies run in Wales are sponsored by an organisation outside Wales.

Source: 2018/19 and 2019/20 performance reports



71

Sponsored by a Welsh NHS organisation  
(No change from 2018/19)

124

Sponsored by Welsh university  
(Up 19 from 2018/19)

422

Sponsored outside Wales  
(Up 46 from 2018/19)

# Performance rating of studies sponsored by NHS Wales organisations


This chart shows the performance rating for both open and closed studies sponsored by NHS Wales organisations.

This shows that self-sponsored studies tend to perform the same or slightly worse than externally sponsored studies in Wales.

## Note:

The data is only included for those organisations that sponsor at least 4 studies.

Source: 2019/20 Performance data



## Location of CI for commercial studies open in Wales

This chart shows that 14% of the Chief Investigators for commercially sponsored studies are located in Wales.



■ CI Based in Wales: 30

■ CI Based Outside of Wales: 189

Source: 2019/20 Performance data

# Section 5

## Research performance in Wales



- Balance of portfolio studies in Wales and trend analysis
- All Wales performance summary against key indicators
- Performance over the last 5 years (number of studies and number of participants recruited)
- Recruitment to target in 2019/20 and over the last 5 years
- Anticipated closure of studies in the current financial year
- Performance status of studies expected to close in 2020/21

## Overview of non-commercial recruitment to portfolio studies in Wales

These charts show an overview of recruitment to studies in Wales.

Note: The data presented is:

- Recruitment to studies in Wales 2015/16 to 2019/20, by study complexity.
- Recruitment to studies in Wales 2015/16 to 2019/20, by NHS organisation and study complexity.
- Percentage recruitment to portfolio studies in Wales 2015/16 to 2019/20, by NHS organisation and study complexity.



Source: ODP

	AB UHB	BC UHB	CTM UHB	CV UHB	HD UHB	Non-NHS	PHW	PTHB	SB UHB	VNHST	WAST
Interventional	23%	25%	16%	35%	21%	31%	57%	43%	34%	55%	91%
Observational	39%	43%	40%	48%	43%	65%	4%	35%	42%	35%	9%
Large Sample	38%	32%	44%	17%	36%	4%	39%	22%	24%	10%	0%

## Delivery framework performance indicators for non-commercial studies in Wales

These charts show performance as an all Wales value and by NHS organisation for indicators relating to the number of studies and number of participants recruited to non-commercial studies.


Grey bars show the target, red bars show actual number where target not met, and green bars show that the target has been met or exceeded.

**Note:** The indicators are defined:


- **C1:** Number of studies on the Health and Care Research Wales Portfolio (10% increase p.a.).
- **D1:** Number of participants recruited into Health and Care Research Wales Portfolio studies (10% increase p.a.).

Source: 2018/19 - 2019/20 Performance Reports


### C1 Performance 18/19 - 19/20




### All Wales



### D1 Performance 18/19 - 19/20



### All Wales



## Delivery framework performance indicators (C1 & D1) for non-commercial studies in Wales

These charts show performance by NHS organisation for indicators C1 & D1 from 2015/16 – 2019/20.

### Note:

This only shows NHS organisations with at least 10 recruiting studies in a financial year.


The indicators are defined:

- **C1:** Number of studies on the Health and Care Research Wales Portfolio (10% increase p.a.).
- **D1:** Number of participants recruited into Health and Care Research Wales Portfolio studies (10% increase p.a.).

Source: 2015/16 – 2019/20  
Performance Data

C1: Open & Recruiting Studies 2015/16 - 2019/20

D1: Recruitment 2015/16 - 2019/20



## Delivery framework performance indicators (C2 & D2) for commercial studies in Wales

These charts show performance as an all Wales value and by NHS organisation for indicators relating to the number of studies and number of participants recruited to commercial studies.


Grey bars show the target, red bars show actual number where target not met, and green bars show that the target has been met or exceeded.

**Note:** The indicators are defined:


- **C2:** Number of commercially sponsored studies (5% increase p.a.).
- **D2:** Number of participants recruited into commercially sponsored studies (5% increase p.a.).

Source: 2018/19 - 2019/20 Performance Reports


### C2 Performance - 18/19 - 19/20




### All Wales



### D2 Performance 18/19 - 19/20



### All Wales





## Delivery framework performance indicators (C2 & D2) for non-commercial studies in Wales


These charts show performance by NHS organisation for indicators C2 & D2 from 2015/16 – 2019/20.

**Note:** The indicators are defined:


- **C2:** Number of commercially sponsored studies (5% increase p.a.).
- **D2:** Number of participants recruited into commercially sponsored studies (5% increase p.a.).

Source: 2015/16 – 2019/20  
Performance Data

C2: Open & Recruiting Studies 2015/16 - 2019/20



D2: Recruitment 2015/16 - 2019/20



## Delivery framework performance indicators C & D: Wales 2015/16 – 2019/20


These charts show the national performance of Wales for indicators C1, C2 & D1, D2 from 2015/16 to 2019/20.

**Note:** The indicator is defined:


- **C1:** Number of studies on the Health and Care Research Wales Portfolio (10% increase p.a.).
- **C2:** Number of commercially sponsored studies (5% increase p.a.).
- **D1:** Number of participants recruited into Health and Care Research Wales Portfolio studies (10% increase p.a.).
- **D2:** Number of participants recruited into commercially sponsored studies (5% increase p.a.).

Source: 2015/16 – 2019/20  
Performance Data

Wales: Open & Recruiting Studies 2015/16 - 2019/20



Wales: Recruitment 2015/16 - 2019/20



**53%** of open non-commercial study-sites recruiting to target in 2019/20

**49%** of closed non-commercial study-sites met their target


## Delivery framework performance indicators (E5) for non-commercial studies in Wales

These charts show performance by NHS organisation for indicator E5.

**Note:** The indicator is defined:

- **E5:** Percentage of Health and Care Research Wales portfolio studies recruiting to target (100% of studies).

Source: 2019/20 Performance data



**33%** of open commercial study-sites recruiting to target in 2019/20

**44%** of closed commercial study-sites met their target



## Delivery framework performance indicators (E6) for commercial studies in Wales

These charts show performance by NHS organisation for indicator E6.

**Note:** The indicator is defined:

- **E6:** Percentage of commercially sponsored recruiting to target (100% of studies).

Source: 2019/20 Performance data








## Delivery framework performance indicators (C1, C2 & E5, E6 Open) 2015/16 – 2019/20

These charts show performance by NHS organisation for indicators C1, C2 & E5, E6 (open studies).

**Note:** The indicator is defined:

- **C1:** Number of studies on the Health and Care Research Wales Portfolio (10% increase p.a.).
- **C2:** Number of commercially sponsored studies (5% increase p.a.).
- **E6:** Percentage of commercially sponsored recruiting to target (100% of studies).

Source: 2015/16 – 2019/20 Performance Data



— No. of Open & Recruiting Non-Commercial Studies

— No. of Open & Recruiting Commercial Studies

— % of Open Studies RAG Rated Green [Non-commercial & Commercial]


## Delivery framework performance indicators (C1, C2 & E5, E6 Open) 2015/16 – 2019/20

These charts show performance by NHS organisation for indicators C1, C2 & E5, E6 (open studies).

**Note:** The indicator is defined:

- **C1:** Number of studies on the Health and Care Research Wales Portfolio (10% increase p.a.).
- **C2:** Number of commercially sponsored studies (5% increase p.a.).
- **E6:** Percentage of commercially sponsored recruiting to target (100% of studies).

Source: 2015/16 – 2019/20 Performance Data



## Delivery framework performance indicators E5 & E6: Wales 2015/16 – 2019/20

These charts show the national performance of Wales for indicators E5, E6 for studies that were open & closed at the end of each financial year from 2015/16 to 2019/20.


A comparison to England's performance of closed studies recruiting to target has also been included.

**Note:** The indicator is defined:


- **E5:** Percentage of non-commercially sponsored recruiting to target (100% of studies).
- **E6:** Percentage of commercially sponsored recruiting to target (100% of studies).

Source: 2015/16 – 2019/20  
Performance Data

### Wales: % Open Studies Recruiting to Time & Target



### Wales / England: % Closed Studies Recruiting to Target



## Anticipated study closure during current financial year by organisation


These charts show the anticipated study closure timelines of studies open during 2019/20 by organisation.

Note: The timeline is divided as:


- Already closed
- Less than 6 months
- Between 6 months and 1 year
- Greater than a year
- Unknown

Source: 2019/20 Performance data

### 2019/20 Study Close Dates



### 2019/20 Studies Expected Close Dates, weighted by recruitment



#### Note:

The weighted by recruitment graph splits the recruitment in 2019/20 by the closure timelines of the recruiting studies. E.g. 60% of PTHB recruitment was to studies that are expected to run for >12 months. 100% of WAST 19/20 recruitment was to studies that had closed by the end of 19/20.



## Performance of studies anticipated to close in 2019/20 by organisation

This chart shows the performance rating of studies that are anticipated to close in 2020/21.


This shows that in general, over half of the studies due to close in 2020/21 are not currently on track to hit their recruitment target.

Note: Studies not marked green shows that these studies are not on track to achieve their agreed recruitment target.

Black studies are either primary care or have missing target data

Source: 2019/20 Performance data

RAG Status of studies expected to close in 2020/21



Appendix 3

COVID-19 Research studies in Swansea Bay UHB

